# Naval Medical Center Portsmouth Allergy/Immunology Referral Guidelines: Allergen Immunotherapy (aka- allergy shots)

#### Definition

- "Allergen immunotherapy is the repeated administration of specific allergens to patients with IgE-mediated conditions for the purpose of providing protection against the allergic symptoms and inflammatory reactions associated with these allergens."
  - Immunotherapy may include pollens, dander, molds, cockroach, dust mite (AIT) as well as stinging insect venom (VIT).
  - o Sublingual immunotherapy (SLIT) is not more effective and is not utilized.

## **Evaluation and Management**

- Candidates for allergen immunotherapy have poorly controlled asthma, rhinitis or life threatening reactions to stinging insects with evidence of clinical sensitization based on skin testing to suspect allergens. AIT is performed as young as 3 years of age.
  - o Blood allergy testing is not used to write an AIT prescription.
- Medical management of patients will continue under the supervision of the allergist.

## **Treatment objectives:**

- At the end of 3-5 years, complete symptom remission and minimal or no medication use.
- Efficacy of therapy is long-lasting, on average 15-25 years or longer in some cases.

#### **Indications for Specialty Evaluation:**

- Referring providers should document that the patient or parent are interested in AIT as a disease modifying therapy in the body of the consult. Ideal candidates:
  - o Persistent asthma, especially if poorly controlled.
  - o Allergic rhinitis unresponsive to consistent use of antihistamines AND nasal steroids.
  - Multiple medications and avoidance measures have failed to adequately control symptoms OR patients desire to decrease their medication burden.
  - o Immediate life threatening reactions to stinging insects (wasp, bees, hornets, yellow jackets or fire ants).
  - o Atopic dermatitis patients with allergic rhinitis or asthma will be considered for AIT.
- PCM's may use blood allergy testing for patients not meeting above criteria.
  - o AHLTA: NC/VA panel < 3 years of age, Wide-RAST > 3 years of age. (Completely negative tests < 0.35 kUa/L effectively exclude allergy.)
  - o <u>www.AAAAI.org</u> or <u>www.ACAAI.org</u> are websites with helpful patient information to guide avoidance measures.

### **Return to Primary Care:**

• The patient does not meet criteria for AIT or is uninterested in treatment after education/counseling and initiation of maintenance therapy.

Reference: Allergen immunotherapy: A practice parameter third update, JAN 2011.